{"DataElement":{"publicId":"6690702","version":"2","preferredName":"CA-125 Antigen Post Neoadjuvant Chemotherapy Result Biomarker Value","preferredDefinition":"Numeric value to represent tumor marker CA-125 at the end of neoajuvant chemotherapy.","longName":"CA125_PST_CHEMO_VAL","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"6689819","version":"1","preferredName":"CA-125 Antigen Post Neoadjuvant Chemotherapy Result","preferredDefinition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumor marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders. (NCI04)_Happening at a time subsequent to a reference time; later in time or order._The administration of therapeutic agents prior to the primary treatment for the purpose of making the primary treatment more effective._The use of synthetic or naturally-occurring chemicals for the treatment of diseases._The result of an action.","longName":"6689813v1.0:6689817v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"6689813","version":"1","preferredName":"CA-125 Antigen","preferredDefinition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumor marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders. (NCI04)","longName":"C325","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CA-125 Antigen","conceptCode":"C325","definition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumor marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"863425D5-A37A-40EA-E053-F662850A95D2","latestVersionIndicator":"Yes","beginDate":"2019-04-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-10","modifiedBy":"ONEDATA","dateModified":"2019-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6689817","version":"1","preferredName":"Post Neoadjuvant Therapy Chemotherapy Outcome","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.:The administration of therapeutic agents prior to the primary treatment for the purpose of making the primary treatment more effective.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.:The result of an action.","longName":"C38008:C15665:C15632:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86346C6B-E586-43FA-E053-F662850A70C0","latestVersionIndicator":"Yes","beginDate":"2019-04-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-10","modifiedBy":"ONEDATA","dateModified":"2019-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"86346C6B-E597-43FA-E053-F662850A70C0","latestVersionIndicator":"Yes","beginDate":"2019-04-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-10","modifiedBy":"HARTLEYG","dateModified":"2019-04-17","changeDescription":"Curated to support Ovarian content","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3008701","version":"1.1","preferredName":"Biomarker Result Value","preferredDefinition":"Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc_The result of an action._A numerical quantity measured or assigned or computed.","longName":"BIOM_RSL_VAL","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3008700","version":"1","preferredName":"Biomarker Outcome Value","preferredDefinition":"Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc:Outcome; a phenomenon that follows and is caused by some previous phenomenon.:A numerical quantity measured or assigned or computed.","longName":"C16342:C20200:C25712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biomarker","conceptCode":"C16342","definition":"A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F390F45-8A3B-F5A0-E040-BB89AD4307B2","latestVersionIndicator":"Yes","beginDate":"2010-02-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-10","modifiedBy":"ONEDATA","dateModified":"2010-02-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8B012E7-104E-589C-E053-4EBD850A8E2B","latestVersionIndicator":"Yes","beginDate":"2020-06-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-06-22","modifiedBy":"COOPERM","dateModified":"2020-06-22","changeDescription":"Increased max length to 4 at OCG request and versioned associated CDEs. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"10000168","version":"1","longName":"Ovarian","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CA-125 at the end of neoadjuv","type":"Preferred Question Text","description":"CA-125 at the end of neoadjuvant chemotherapy","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8B01D07-D019-5CCB-E053-4EBD850A4E53","latestVersionIndicator":"Yes","beginDate":"2020-06-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-06-22","modifiedBy":"COOPERM","dateModified":"2020-06-22","changeDescription":"Curated to support Ovarian content. Increased VD max length to 4 at OCG request and versioned associated CDEs. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}